An independent review on the lamotrigine sole-supply decision has found that PHARMAC’s processes were evidence based and robust, and of a high standard.
From Monday a new medicine is being funded by PHARMAC which will help young children with cystic fibrosis digest their food more easily.
PHARMAC is placing temporary dispensing limits on all funded community medicines from Friday 27 March 2020.
Around 500 New Zealanders who have severe asthma will have access to a new medicine, mepolizumab, from next month.
PHARMAC is placing temporary dispensing limits on Government-funded paracetamol from Monday 9 March 2020.
New Zealanders with advanced breast cancer will be able to access palbociclib (marketed as Ibrance) from 1 April this year, which could stop or slow down the progression of their cancer.
PHARMAC has reached a provisional agreement with medicine supplier Vertex to fund ivacaftor (marketed as Kalydeco) for people with cystic fibrosis.
PHARMAC is seeking proposals from pharmaceutical suppliers for new medicines that could help New Zealanders living with type 2 diabetes
PHARMAC has reached a provisional agreement with medicine supplier Pfizer to fund palbociclib (marketed as Ibrance) for first-line and second-line treatment of certain types of breast cancer.
PHARMAC has published the Rare Disorders Subcommittee meeting records which recommends Spinraza (nusinersen), a medication for spinal muscular atrophy, is funded in New Zealand.
Thousands of New Zealanders with lymphoma, breast, ovarian and blood cancers will have more treatment options available to them in the New Year.
Patients taking lamotrigine who have concerns about the change can talk with their doctor about remaining on their current brand as PHARMAC has widened the criteria for lamotrigine exceptional circumstances.
The meningococcal ACWY vaccine will be available free from next month for young people in close living situations.
New Zealanders with chronic lymphocytic leukaemia will have another medicine option available to help them live longer from 1 December 2019.
PHARMAC is widening funded access to Mirena, as well as listing a new long-acting reversible contraceptive option, Jaydess, which will benefit around 21,000 New Zealand women.
420 New Zealanders with lung cancer, breast cancer, multiple sclerosis and respiratory disease will benefit each year from a bundle deal PHARMAC has finalised with a medicine supplier.
The agreement with Roche Products (New Zealand) includes funding three new treatments, as well as widened access to one currently funded treatment.
From today there will be one funded brand of lamotrigine - a medicine used to treat epilepsy and some mental health conditions, including bipolar disorder.
There are several suppliers that make lamotrigine – each with their own brand. PHARMAC has decided to change from funding three different brands (Lamictal, Arrow-Lamotrigine and Logem) to funding the Logem brand only.
PHARMAC has reached a deal with pharmaceutical companies for three new medicines to treat ovarian cancer, breast cancer and leukaemia.
PHARMAC and Ngā Pou Mana (NPM) are calling for scholarship award nominations for Māori kaimahi, students and community members who have had a positive impact on whānau, hapū and iwi.
Up to 50,000 New Zealanders per year will benefit from a new multiproduct agreement PHARMAC has reached with Novartis, which makes more funded medicines available for a wide range of health conditions.